Fenofibrate Treatment Enhances Antioxidant Status and Attenuates Endothelial Dysfunction in Streptozotocin-Induced Diabetic Rats

Table 2

E_max and 𝑝D₂ values for control and diabetic rats.

	Emax				𝑝D2
	C	D	D + FF	C + FF	C	D	D + FF	C + FF
Phenylephrine E(+)	1002±57	1449±61^∗	952±83^#	1038±103	7.09±0,13	7.10±0,61	6.83±0,81	7.71±0.17
Phenylephrine E(−)	1562±244	1432±237	1534±437	1390±711	7.71±0.51	7.66±0.33	7.59±0.36	7.85±0.43
Acetylcholine	85.00±0.30	67.63±0.23^∗	89.08±0.35^#	82.00±0.35	7.34±0.03	7.26±0.05	7.44±0.04	7.33±0.06
A23187	74.08±0.29	68.5±0.20	72.88±0.33	74.37±0.31	6.73±0.09	6.72±0.04	6.37±0.06	6.14±0.06
L-Arginine	78.21±0.20	68.2±0.20	74.70±0.36	84.75±0.95	5.66±0.05	5.73±0.04	5.98±0.07	5.79±0.19
Sodium nitroprusside	80.34±0.22	74.69±0.16	71.73±0.36	74.06±0.74	6.75±0.06	6.80±0.03	6.94±0.06	6.79±0.12

Data are expressed as mean ± SEM, 𝑛=10.
E_max is defined as the ratio of phenylephrine precontraction to maximum relaxation of acetylcholine, L-arginine, sodium nitroprusside, and calcium inonophore A23187.
𝑝D₂ is defined as −log EC₅₀ concentration of drugs.
C: control; DM: diabetes mellitus; FF: fenofibrate; E(+): endothelium-intact aorta; E(−): endothelium-denuded aorta.
* 𝑃<.05 versus C, ^#𝑃<.05 versus DM.